home / stock / alpmy / alpmy quote
Last: | $10.04 |
---|---|
Change Percent: | 1.71% |
Open: | $9.8 |
Close: | $10.04 |
High: | $10.3 |
Low: | $9.8 |
Volume: | 257,703 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.04 | $9.8 | $10.04 | $10.3 | $9.8 | 257,703 | 05-03-2024 |
$9.97 | $9.99 | $9.97 | $10.02 | $9.96 | 310,908 | 05-02-2024 |
$9.7 | $9.46 | $9.7 | $9.7 | $9.46 | 124,459 | 05-01-2024 |
$9.55 | $9.5 | $9.55 | $9.67 | $9.5 | 262,496 | 04-30-2024 |
$9.63 | $9.6 | $9.63 | $9.69 | $9.57 | 338,667 | 04-29-2024 |
$9.55 | $9.54 | $9.55 | $9.59 | $9.53 | 452,047 | 04-26-2024 |
$9.54 | $9.59 | $9.54 | $9.645 | $9.51 | 500,673 | 04-25-2024 |
$9.47 | $9.39 | $9.47 | $9.47 | $9.36 | 403,828 | 04-24-2024 |
$9.49 | $9.5 | $9.49 | $9.54 | $9.48 | 484,942 | 04-23-2024 |
$9.53 | $9.56 | $9.53 | $9.56 | $9.47 | 694,616 | 04-22-2024 |
$9.5 | $9.59 | $9.5 | $9.64 | $9.48 | 1,002,027 | 04-19-2024 |
$9.47 | $9.46 | $9.47 | $9.5 | $9.39 | 518,030 | 04-18-2024 |
$9.46 | $9.2201 | $9.46 | $9.5 | $9.2201 | 502,581 | 04-17-2024 |
$9.34 | $9.15 | $9.34 | $9.42 | $9.15 | 692,432 | 04-16-2024 |
$9.2715 | $9.51 | $9.2715 | $9.51 | $9.25 | 501,103 | 04-15-2024 |
$9.55 | $9.4 | $9.55 | $9.7 | $9.24 | 301,955 | 04-12-2024 |
$10.29 | $10.5 | $10.29 | $10.5 | $10.26 | 529,566 | 04-11-2024 |
$10.234 | $10.44 | $10.234 | $10.44 | $10.21 | 196,394 | 04-10-2024 |
$10.47 | $10.1 | $10.47 | $10.5 | $10.1 | 386,762 | 04-09-2024 |
$10.52 | $10.28 | $10.52 | $10.69 | $10.28 | 388,102 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurr...